{"id":"xalatan-de-130a","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"conjunctival hyperemia"},{"rate":"10-20%","effect":"eye itching"},{"rate":"5-10%","effect":"eye pain"},{"rate":"5-10%","effect":"foreign body sensation in the eye"},{"rate":"<5%","effect":"diplopia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Xalatan works by mimicking the action of a natural prostaglandin, prostaglandin F2α, which is involved in the regulation of intraocular pressure. By increasing uveoscleral outflow, Xalatan reduces the pressure in the eye, thereby reducing the risk of glaucoma progression.","oneSentence":"Xalatan is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:07.217Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04133311","phase":"PHASE3","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-04-10","conditions":"Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease","enrollment":386}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Catiolanze®"],"phase":"phase_3","status":"active","brandName":"Xalatan®/DE-130A","genericName":"Xalatan®/DE-130A","companyName":"Santen SAS","companyId":"santen-sas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xalatan (latanoprost) is used to treat Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease. It is compared to DE-130A in clinical trials for efficacy and safety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}